CorMedix
CRMD
102 hedge funds and large institutions have $155M invested in CorMedix in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 15 closing their positions.
108% more capital invested
Capital invested by funds: $74.3M → $155M (+$80.4M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
77% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 22
34% more call options, than puts
Call options by funds: $5.85M | Put options by funds: $4.35M
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3.05% more ownership
Funds ownership: 31.23% → 34.28% (+3.1%)
3% more funds holding
Funds holding: 99 → 102 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$7.98M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$3.9M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.06M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$1.48M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$6.16M |
| 2 |
Millennium Management
New York
|
-$1.93M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$785K |
| 4 |
Two Sigma Investments
New York
|
-$706K |
| 5 |
Renaissance Technologies
New York
|
-$696K |
CRMD Hedge Fund Activity: Q3 2024 in Review
102 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2024, worth a combined $155M — up 108% from $74.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CRMD positions and 15 closed out — a net gain of 3 holders — while 39 added to existing stakes and 22 trimmed.
The largest buyer was Rosalind Advisors, opening a new position worth an estimated $7.98M. The largest seller was Nomura Holdings, exiting entirely with an estimated $6.16M sold.
- 102 institutional investors held CorMedix (CRMD) as of Q3 2024, up from 99 in Q2 2024.
- Funds reported $155M of CorMedix stock for Q3 2024, up 108% quarter-over-quarter.
- 18 funds opened new CorMedix positions in Q3 2024 and 15 closed out, a net change of +3 holders.
- The largest CorMedix buyer in Q3 2024 was Rosalind Advisors, an estimated $7.98M added.
- The largest CorMedix seller in Q3 2024 was Nomura Holdings, an estimated $6.16M sold.
Based on aggregated 13F filings for Q3 2024.